Hence, combining C15orf48 inhibition with NF-κB inhibitors might result in a dual pathway blockade, offering a more effective therapeutic approach for NSCLC patients resistant to traditional therapies. This evidence concerns the gene NFKB1 and non-small cell lung carcinoma.